SBIR Phase I: Rapid Development of a Protein Vaccine for COVID-19

SBIR 第一阶段：快速开发针对 COVID-19 的蛋白质疫苗

• 批准号: 2036226
• 负责人: Peter Leonardi
• 金额: $ 25.6万
• 依托单位: OMNICYTE, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-10-01 至 2021-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2036226&HistoricalAwards=false
• 关键词: SBIR; Phase; Rapid; Development; Protein

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is the development of a vaccine to prevent infection from the SARS-CoV-2 virus. The proposed project is a novel vaccine that activates multiple components of the immune system, potentially more effective than other SAR-CoV-2 vaccines, and using a well-understood approach as a protein-based vaccine.This SBIR Phase I project will advance a protein vaccine based upon a platform technology combining two functions, activating the immune system and targeting it to attack to a specific pathogen or cell. The platform has a modular design that allows it to be re-engineered, in a cassette-like fashion, to redirect the attack to different targets. Applications for the technology include vaccines against viruses and cells infected by viruses, as well as against specific cancer types. The vaccine can be rapidly generated and easily re-engineered. The focus of this project will be to produce this SARS-CoV-2 targeted protein vaccine utilizing an immune-activating platform with the SARS-CoV-2 spike protein inserted into the targeting domain of the platform. The will be followed by studies to demonstrate the vaccine candidate activity in an in vitro model and an animal model.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这一小型企业创新研究（SBIR）第一阶段项目的更广泛影响/商业潜力是开发预防SARS-CoV-2病毒感染的疫苗。 该项目是一种新型疫苗，它可以激活免疫系统的多种成分，可能比其他SAR-CoV-2疫苗更有效，并使用众所周知的蛋白质疫苗方法。SBIR第一阶段项目将基于平台技术开发蛋白质疫苗，该平台技术结合了两种功能，激活免疫系统并将其靶向攻击特定病原体或细胞。 该平台具有模块化设计，可以以类似盒式磁带的方式重新设计，将攻击重定向到不同的目标。 该技术的应用包括针对病毒和被病毒感染的细胞以及针对特定癌症类型的疫苗。 疫苗可以快速生成，并且很容易重新设计。本项目的重点将是利用免疫激活平台，将SARS-CoV-2刺突蛋白插入平台的靶向结构域中，生产这种SARS-CoV-2靶向蛋白疫苗。该奖项反映了NSF的法定使命，并被认为值得通过使用基金会的知识价值和更广泛的影响审查标准进行评估来支持。